Valle d’Aosta

Abstract

In Aosta Valley region 77,9% of women (aged 25-64) are screened regularly, meaning every 3 years. Considering regional tariffs and vaccine acquisition cost, the vaccination of 12-year-old girls with a 90% coverage could prevent 2 cases of cervicocarcinoma and 1 related death and thus results to be cost-effective (33.211 €/QALY). When the vaccination programme is extended to 16-year-old girls a further 1 cancer case could be prevented, with a very similar cost-effectiveness ratio. In Aosta Valley region, the net cost for woman vaccinated is 209 € for the single cohort and 211 € for the multiple cohort.

Keywords

• aosta valley
• hpv vaccination
• economic & clinical impact